Lung cancer is the most common cause of cancer related death in the world, and the incidence is still increasing. Although several therapies are available for advanced disease, they are palliative and the cure rate remains very low for patients. New therapeutic strategies are required to improve the poor prognosis of patients with non-small-cell lung cancer (NSCLC).

Notch receptor is a single-pass transmembrane protein, which regulates cell-fate determination in multi-cellular organisms. In mammals, there are four Notch receptors (Noch1--Notch4) and two families of ligands, Jagged (Jagged1 and -2) and Delta--like (Dll-1, -3 and -4) ([@bib1]; [@bib19]). Upon ligand binding, the Notch receptor undergoes a number of proteolytic cleavages. The final cleavage by the *γ*-secretase complex releases the Notch intracellular domain (NICD), which forms a nuclear complex with transcription factor CSL (CBF1, Sel, Lag-1) and induces expression of target genes, such as the Hairy and enhancer of split (*HES*) and Hairy/enhancer of split related with YRPW (*HEY*) gene family ([@bib38]).

Several studies have highlighted the aberrant activation of Notch pathways in tumourigenesis of many cancers ([@bib7]; [@bib5]; [@bib10]; [@bib28]). We have demonstrated that Notch3 is expressed in ∼40% of NSCLC tumours and that suppression of Notch3 by dominant negative or *γ*-secretase inhibitor (GSI) inhibits growth of lung cancer both *in vitro* and *in vivo* ([@bib17]; [@bib20]). *γ*-Secretase inhibitor modulates the Bcl-2 family proteins and downregulates MAPK pathway ([@bib20]). Our group also reported that Bim, BH3-only member of the Bcl-2 family proteins, is necessary for Notch3-dependent apoptosis and that the effect of Notch3 on Bim is through MAPK regulation ([@bib21]).

Although radiotherapy is routinely used to treat patients with lung cancer, resistance to radiation is one of the major reasons for radiotherapy failure in NSCLC. While many factors have been proven contributing to this observation, radiation has been shown to activate Notch in breast cancer and glioma. Given the role of Notch signalling in oncogenesis, these observations suggest that Notch represents a mechanism of radioresistance ([@bib26]; [@bib36]).

In this study, we demonstrated the enhanced antitumour effect of GSI after radiation in Notch expressing lung cancer cell lines *in vitro* and *in vivo*. We also provide evidence that the observed antitumour effect involves Notch pathway. The mechanism involves apoptosis through the regulation of MAPK and Bcl-2 family proteins. Thus, our findings will help define a new strategy in modulating radiation therapy to enhance clinical efficacy in the treatment of patients with NSCLC.

Materials and methods
=====================

Cell lines and inhibitors
-------------------------

HCC2429 was established as previously described ([@bib6]). The NSCLC cell lines, H460, A549 and H1395 were obtained from American Type Culture Collection (Manassas, VA, USA). Cell lines were maintained in RPMI supplemented with 10% foetal calf serum at 37 °C in a humid environment in 5% CO~2~. *γ*-Secretase inhibitor I (*in vitro*) and GSI XX (*in vitro, in vivo*) were obtained from Calbiochem (San Diego, CA, USA).

MTT proliferation assay
-----------------------

HCC2429 at 10 000 cells per well, H460 and H1395 at 500 cells per well were seeded into a 96-well plate and incubated overnight. HCC2429 and H460 were shown previously to have high Notch3 expression, whereas H1395 did not express Notch ([@bib20]). The cells were treated with GSI I and radiation simultaneously, radiation at 24 h after GSI I or GSI I at 24 h post-radiation. Treated cells were then incubated for 8 days. The MTT assay was performed to according to manufacturer\'s recommendation. The absorption was determined at 560 nm using the microplate reader (Varioskan Flash; Thermo Fisher Scientific, Lafayette, CO, USA).

Clonogenic assay
----------------

HCC2429 at 5000 cells per well, H460 and H1395 at 2000 cells per well were plated on 6-well plate and were then irradiated with 0 to 4 Gy as indicated after an overnight incubation. *γ*-Secretase inhibitor I at varying doses was added at 24 h after radiation and cells were incubated for 8 days. The cells were then fixed and stained for 1 min with 0.5% crystal violet in methanol. The number of colonies was counted manually. Survival fraction was calculated using the following formula: mean colony counts/cells inoculated × plating efficiency (PE). PE was defined as: mean colony counts/cells inoculated for unirradiated controls, as previously described ([@bib2]).

Quantification of interaction of combination
--------------------------------------------

Combination index (CI) for the GSI and radiation was described previously ([@bib4]; [@bib14]). Accordingly, CI was calculated as follows:

Where Dx is the dose of radiation and Cx is the dose of GSI that yields a selected level of survival (*x*) when each agent is used alone. *D* is the dose of radiation and *C* is the dose of GSI that yields the same survival (*x*) when both treatments were combined. The level of survival selected to evaluate each set of combined treatments is lower than the survival following radiation alone. Combination index values are smaller than, equal to or greater than 1 represent supra-additive, additive and sub-additive effects of the combined treatment, respectively.

Apoptosis assays
----------------

HCC2429 and H460 were plated onto 6-well plates at the density of 1 × 10^6^ cells per well and 3 × 10^5^ cells per well respectively, incubated overnight, and subsequently treated with GSI I 1 *μ*ℳ for HCC2429 and 9 *μ*ℳ for H460 24 h after 8 Gy of radiation. HCC2429 and H460 were then incubated for 24 and 48 h, respectively. The cells were stained with FITC-conjugated Annexin V and propidium iodide (PI), using Annexin V-FITC Apoptosis Detection kit and according to manufacturer\'s recommendation (Calbiochem). The percentage of apoptotic cells was determined using a flow cytometry (BD FACSCalibur; Becton, Dickinson and Company, Franklin Lakes, NJ, USA).

Antibodies and western blot analysis
------------------------------------

Notch3 was detected using a rabbit polyclonal antibody from Allele Biotechnology and Pharmaceuticals, Inc. (San Diego, CA, USA) at 1 : 500. Notch1 was detected using a mouse monoclonal antibody from Sigma-Aldrich Corp. (St Louis, MO, USA) at 1 : 500. The rabbit antibodies to HES1 and HEY1 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The rabbit antibodies to Bcl-xL, phosphor-Bcl-2 (p-Bcl-2), Bcl-2, extracellular signal-regulated kinase (ERK), p-ERK, AKT, p-AKT and poly (ADP-ribose) polymerase (PARP) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Bim antibody was obtained from Sigma-Aldrich Corp. The band intensity was demonstrated by quantitative densitometric analysis using NIH Image Ver1.62 software (NIH, Bethesda, MD, USA). Standardisation was performed with actin measured in the same blots with anti-actin antibody (A-2066, Sigma-Aldrich Corp.). Quantifications were shown by the ratios of treated protein expression/untreated protein expression.

*In vivo* tumourigenicity
-------------------------

All animal husbandry and experiments were performed under a protocol approved by Institutional Animal Care Committee at Hokkaido University School of Medicine. H460 and A549 at 1.0 × 10^6^ cells were diluted in 100 *μ*l of PBS and injected subcutaneously into right posterior legs of athymic, 5-week-old, female nude mice (*nu+/nu+*). When the tumours were palpable, the mice were randomly assigned to the radiation group, the GSI group, the combination group or the control group. Each group consisted of five mice. The mice in the radiation alone group received 8 Gy of radiation at day 1 and 8. The radiation was administered to the tumour with the remainder of the body shielded with lead. In the GSI group, 200 *μ*g kg^−1^ GSI XX was administered by i.p. at day 2, 3, 4 and 9, 10, 11, as previously described ([@bib35]; [@bib21]). The combination group received both GSI XX and radiation in similar schedule. The tumours were then measured every 2 days using a digital caliper. Tumour volume (TV) was determined using the formula: TV=(Length) × (Width) × (Height)/2 ([@bib2]). Tumour growth rate (%TV) on day X was calculated as: (TV on day X/TV on day1) × 100, as previously described ([@bib21]). Some tumours were resected on day 15 and the expression of NICD3 was determined by western blot analysis.

Statistical analysis
--------------------

Determination of significance between the control and observation arms of both *in vitro* and *in vivo* assays was analysed using the non-parametric Mann--Whitney *U* test. Statistical significance was established at the *P* value\<0.05. Calculations were performed using SPSS, version 11.0.1 (SPSS Inc., Chicago, IL, USA).

Results
=======

Treatment with GSI at 24 h after radiation enhanced growth inhibition of lung cancer *in vitro*
-----------------------------------------------------------------------------------------------

To determine whether the combining GSI and radiation can inhibit lung cancer proliferation, we treated Notch expressing lung cancer cell lines, HCC2429 and H460 with increasing dose of GSI and radiation. Cell viability of both cell lines was determined using the MTT assay. Neither concurrent treatment schedule nor radiation after GSI I administration had a significant impact on tumour proliferation compared with single treatment with GSI I alone (0 Gy) ([Figure 1A](#fig1){ref-type="fig"}). In contrast, when GSI I was administrated after radiation, there was a significant decrease in IC~50~ of GSI I compared to treatment with GSI I alone (0 Gy) in HCC2429 and H460 ([Figure 1B](#fig1){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Clonogenic assay was performed to confirm the results of the MTT assay. This treatment schedule resulted in greater suppression in colony formations compared with radiation alone ([Figure 1C](#fig1){ref-type="fig"}). On the other hand, in H1395, which does not express Notch, no difference between single treatment and combination was observed in IC~50~ and colony formations ([Figure 1B and C](#fig1){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}), suggesting that combination is only effective in Notch expressing cell lines. By determining the CI values of GSI I after radiation in HCC2429 and H460, we noted supra-additive or additive effects of combination in the most set of combining treatment ([Table 1](#tbl1){ref-type="table"}). Therefore, this sequential treatment schedule was employed in all of the following experiments.

GSI prevents radiation-dependent Notch activation
-------------------------------------------------

When HCC2429 and H460 were treated with GSI I alone, the expression of NICD in both cell lines was decreased in a dose-dependent manner ([Figure 2A](#fig2){ref-type="fig"}). To investigate the effect of radiation on Notch pathway, the expressions of NICD1, NICD3 and target genes, *HES1* and *HEY1* were assessed after cells were irradiated at 2 and 4 Gy, respectively. In HCC2429, the expression of NICD1 was upregulated at 24 h after radiation and this upregulation was observed up to 48 h following radiation, whereas the expression of NICD3 was unchanged. Notch1 mRNA was also upregulated after radiation, suggesting that radiation induces transcripts of Notch1 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). In H460, in which the baseline expression of Notch3 level is lower, NICD3 expression was increased at 24 and 48 h after radiation and the expression of NICD1 was not induced by radiation ([Figure 2B](#fig2){ref-type="fig"}). Notch3 mRNA was upregulated after radiation in H460 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). HEY1 expression was upregulated in both cell lines at 48 h after radiation compared with control. Then, we examined NICD1 and NICD3 expression when cells were treated with GSI I, radiation or the combination treatment. Radiation-induced NICD1 upregulation was ameliorated by the combination in HCC2429. Radiation-induced NICD3 enhancement was also reduced by the combination in H460 ([Figure 2C](#fig2){ref-type="fig"}).

Addition of GSI enhances radiation-induced apoptosis
----------------------------------------------------

To examine whether addition of GSI following radiation can induce apoptosis compared either treatment alone, we treated HCC2429 and H460 with GSI I after radiation and determined the proportion of apoptotic cells using Annexin V and PI and flow cytometry ([Figure 3A](#fig3){ref-type="fig"}). Either treatment induced apoptosis. However, the combination increased apoptotic cells two or three fold compared with either treatment alone ([Figure 3B](#fig3){ref-type="fig"}). When GSI XX was used, we also noted the higher induction of apoptosis in NSCLC cell lines (HCC2429, H460 and A549) with radiation compared with either treatment alone ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

Combination alters p-ERK, anti-apoptotic proteins, and pro-apoptotic proteins
-----------------------------------------------------------------------------

As Notch has been shown to crosstalk with the epidermal growth factor receptor pathway ([@bib17]), we assessed the expression of phospo-ERK, a member of the MAPK family and phospho-AKT. The combination reduced the expression of p-ERK compared with either GSI I or radiation alone ([Figure 4A](#fig4){ref-type="fig"}). Although several studies have shown the crosstalk between Notch pathway and phosphatidylinositol 3-kinase (PI3K)/AKT pathway ([@bib37]; [@bib25]), we observed no effect on p-AKT level in any of the treatments ([Figure 4A](#fig4){ref-type="fig"}).

To confirm the effect of the combination on apoptosis, we examined the expression of the Bcl-2 family proteins. We found that the combination reduces levels of anti-apoptotic proteins, p-Bcl-2 and Bcl-xL, and increases pro-apoptotic protein Bim, compared with either GSI I or radiation alone in both cell lines. Furthermore, cleaved PARP was induced in single treatment and combination in both cell lines ([Figure 4B](#fig4){ref-type="fig"}).

Combination enhances antitumour activity *in vivo*
--------------------------------------------------

To determine the effect of combining GSI with radiation *in vivo*, we utilised a xenograft model. We previously have shown that GSI suppressed tumour growth of Notch expressing lung cancer cell lines, H460 and A549 *in vivo* ([@bib20]). The scheduling of radiation and GSI was outlined in [Figure 5A](#fig5){ref-type="fig"} based on our previous findings ([@bib20]; [@bib35]). The radiation was given on days 1 and 8 at 8 Gy per dose, and GSI XX 200 *μ*g kg^−1^ was administered by i.p. injection on days 2--4 and 9--11. We noted a significant delay in growth of tumours in the combination group compared with either of the treatments alone ([Figure 5B](#fig5){ref-type="fig"}). Some tumours were resected on day 15 for molecular analysis. Consistent with our *in vitro* findings, expression of activated NICD3 was enhanced in tumours treated with radiation, and this activation was mitigated by the addition of GSI ([Figure 5C](#fig5){ref-type="fig"}). This observation supports our hypothesis that induction of Notch pathway by radiation is one mechanism of resistance to radiation and can be ameliorated by the addition of GSI. Intestinal toxicity has been major concern in using GSI owing to the loss of intestinal crypts cells and hyperplasia of intestinal goblet cells ([@bib15]). Others reported the observed gut toxicity from GSI was mitigated with intermittent dosing ([@bib34]). We stained intestine of treated mice with periodic acid schiff to examine the intestinal toxicity of GSI. No increase of intestinal goblet cells was seen among treated mice compared with controls (data not shown). Furthermore, no body weight loss was encountered (data not shown), indicating that all treatments, including the combination therapy was well tolerated.

Discussion
==========

Radiation therapy is the primary treatment for patients with locally advanced lung cancer. Although it is very effective in local control, majority of patients will die of their disease, suggesting that further studies are needed to better understand the mechanisms of radiation resistance and to develop new strategies to improve radiation-dependent tumour cytotoxicity.

The phenotypic outcome of Notch signalling is often context-dependent. In lung cancer, Notch1 was known to suppress tumour proliferation under normoxia, but in hypoxia, it had a converse role in tumour promotion ([@bib3]). Moreover, the specific role of each individual Notch receptor in radiation is not fully understood, but our present observation that Notch1, but not Notch3, was enhanced by radiation in HCC2429 also suggests that the biological function of Notch depends on treatment context, suggesting that targeting specific Notch receptor may lead to better outcome by preventing unnecessary toxicity.

In breast cancer, Notch signalling is activated after radiation, suggesting that activation of this oncogenic pathway is a mechanism of radiation resistance ([@bib26]). We hypothesised that Notch activation by radiation has radioprotective role in lung cancer, this phenomenon can be prevented by the use of Notch inhibitors after radiation. In our study, we also showed that radiation-induced Notch activation, which was mitigated by the administration of GSIs, supporting our hypothesis and providing a rationale for the sequential treatment schedule.

Enhanced induction of PARP and reduction of pro-survival proteins, such as p-Bcl-2 and Bcl-xL, by the combination therapy suggested that the observed antitumour effect is mediated through induction of apoptosis. Our findings are compatible with the other reports that GSI or radiation activates the apoptosis pathway, including Bcl-2 family ([@bib20]; [@bib16]; [@bib40]). Some studies have shown that Notch regulated the AKT pathway in several cancers ([@bib23]; [@bib25]; [@bib11]), but expression of p-AKT was unchanged in our study, suggesting that the crosstalks between Notch and other oncogenic pathways are context-dependent.

Cancer stem cells (CSCs) are a small population of cells that are responsible for tumour maintenance and spreading ([@bib29]; [@bib24]). CSCs in lung cancer have been isolated and functions have been described in several reports ([@bib18]; [@bib13]). CSCs are further reported to contribute to resistance of chemotherapy or radiation ([@bib26]; [@bib18]; [@bib13]; [@bib8]; [@bib31]). Notch pathway was activated in several types of CSCs, including colon cancer, breast cancer and glioma ([@bib9]; [@bib27]; [@bib33]). For example, radiation appeared to enhance Notch pathway in both breast cancer (CD24^−/low^/CD44^+^) and glioma (CD133^+^) stem-like cells. The activation of these cells was accompanied by radioresistance ([@bib26]; [@bib36]). We did not examine how the combination therapy affects lung CSCs, as it is unclear that similar markers such as CD133 or CD44 can be used as markers for lung CSC. However, our study suggests GSI prevents the induction of CSCs by radiation, leading to the reduction of tumour growth.

*In vivo*, we observed a statistically significant delay of tumour growth in mice with combination therapy. GSI inhibited NICD both *in vitro* and *in vivo* and might get biochemical inhibition at much lower doses used *in vivo* than used *in vitro.* This suggests to us that the microenvironment contributes to the observable effect. For example, the Notch ligand DLL4 has a critical role in the angiogenesis ([@bib30]; [@bib32]) and GSI has been shown to inhibit tumour growth through preventing DLL4-dependent angiogenesis ([@bib22]). Furthermore, hypoxic tumour environment induces radiation resistance ([@bib39]. Notch 1 was activated under hypoxia in lung cancer cell lines and GSI-induced apoptosis of these cells ([@bib3]; [@bib12]). From these observations and our data, GSI may not only inhibit tumour cells but also tumour microenvironment, which promotes tumour survival.

In summary, our data provided the evidence that the addition of GSI enhanced the cytotoxicity of radiation in lung cancer both *in vitro* and *in vivo*. Because of the role of Notch signalling in tumour hypoxia and CSCs, the radiation-dependent Notch activation likely represents a mechanism of radioresistence. Further studies are needed to ascertain our hypothesis. Nevertheless, our study provides compelling evidence that combining GSI and radiation represents a rational strategy for the treatment of patients with NSCLC.
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![GSI after radiation suppressed proliferation of lung cancer. (**A**) Comparison of IC~50~ values in the different treatment schedule in the MTT proliferation assay. Neither concurrent treatment schedule nor radiation after GSI I administration had a significant impact on tumour proliferation compared with GSI I alone (0 Gy). Plated cells were treated with GSI I and radiation simultaneously or radiation at 24 h after GSI I administration (*n*=5). Treated cells were incubated for 8 days. GSI/R: concurrent treatment schedule. GSI→R: radiation after GSI I administration. (**B**) Comparison of IC~50~ in GSI I after radiation. Plated cells were treated with GSI I at varying doses at 24 h after radiation. IC~50~ was less for combined therapy than for GSI I alone in both HCC2429 and H460 cell lines (*n*=5). \**P*\<0.05. On the contrary, IC~50~ was not different between GSI alone and combination in H1395. (**C**) GSI I after radiation decreased clonogenic survival in HCC2429 and H460, but not in H1395 (*n*=3). Cells were plated overnight and then exposed to radiation with 0 to 4 Gy as indicated. GSI I at varying doses was added at 24 h after radiation and then cells were incubated for 8 days.](bjc2012178f1){#fig1}

![Combination and either GSI or radiation alone regulated the Notch pathway. (**A**) GSI suppressed Notch intracellular domain (NICD) expression in a dose-dependent manner. GSI I downregulated NICD1 and NICD3 in HCC2429, whereas NICD3 in H460. (**B**) Radiation upregulated NICD1, but not NICD3 in HCC2429, whereas NICD3 in H460 at 24 h after radiation (2 or 4 Gy). The downstream Notch target gene, HEY1, was also upregulated at 48 h after radiation. (**C**) Radiation-induced Notch upregulation was ameliorated by the combination. Standardisation was performed with actin measured in the same blots with anti-actin antibody. Quantifications were shown by the ratios of treated protein expression/untreated protein expression.](bjc2012178f2){#fig2}

![Combination treatment induced apoptosis of lung cancer. Cells were treated with GSI I (1 *μ*ℳ in HCC2429 and 9 *μ*ℳ in H460) at 24 h after 8 Gy of radiation. The percentage of apoptotic cells was measured using Annexin V and propidium iodide (PI) with flow cytometry. (**A**) Representative data of four independent experiments on HCC2429 and H460. (**B**) Mean percentage of apoptotic cells. Combination therapy induced significantly higher apoptosis in HCC2429 and H460 cells (*n*=4). \**P*\<0.05.](bjc2012178f3){#fig3}

![Apoptosis was induced through the MAPK pathway and Bcl-2 family proteins by the combination of GSI and radiation. Cells were treated with GSI I (1 *μ*ℳ in HCC2429 and 9 *μ*ℳ in H460) at 24 h after 8 Gy of radiation. (**A**) Combination therapy downregulated p-ERK, but had no effect on p-AKT in either HCC2429 or H460. (**B**) Combination therapy downregulated anti-apoptotic proteins, p-Bcl-2 and Bcl-xL, and upregulated apoptotic proteins, Bim and cleaved PARP, in both HCC2429 and H460.](bjc2012178f4){#fig4}

![Combination therapy inhibited tumour growth of lung cancer *in vivo*. (**A**) Treatment schedule *in vivo*. H460 and A549 at 1.0 × 10^6^ cells were inoculated subcutaneously into right posterior legs of nude mice. Treatment was initiated when tumours were palpable. Mice were treated with 200 *μ*g kg^−1^ GSI XX injected intraperitoneally 3 days per week after 8 Gy of radiation once a week. Tumour size was measured every 2 days. Some tumours were removed on day 15 and the expression of NICD3 was examined by western blot analysis. (**B**) Combination treatment showed the significant delay of tumour growth, compared with control or single treatment alone (*n*=5). (**C**) NICD3 expression was upregulated in H460 and A549 tumour treated with radiation. In contrast, combination therapy reduced NICD3 expression.](bjc2012178f5){#fig5}

###### Combination index (CI) with respect to survival fraction of HCC2429 and H460 cells exposed to GSI I after radiation

  **HCC2429**   **H460**                                   
  ------------- ---------- ------ ------ ---- ----- ------ ------
  50            2.0        0.47   0.96   50   2.0   1.29   0.93
  50            3.0        0.28   1.00   50   3.0   0.98   1.00
  50            4.0        0.20   1.10   50   4.0   0.68   1.21
  25            2.0        0.56   0.78   25   2.0   1.64   0.83
  25            3.0        0.45   0.86   25   3.0   1.56   0.99
  25            4.0        0.31   0.87   25   4.0   1.46   1.10
  10            2.0        0.66   0.66   10   2.0   2.43   0.84
  10            3.0        0.65   0.76   10   3.0   2.26   0.91
  10            4.0        0.64   0.86   10   4.0   1.98   0.94

Abbreviations: CI=combination index; GSI=*γ*-secretase inhibitor.

C and D were obtained from the survival fraction curve (Figure 1C).

CI was calculated for different levels of survival fraction according to [Equation 1](#equ1){ref-type="disp-formula"}.
